Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & ISI's SCI  
Users online: 632  
Home | Subscribe | Feedback | Login 
About Latest Articles Back-Issues Article Submission Resources Sections Etcetera Contact
 
  NAVIGATE Here 
  Search
 
  
 RESOURCE Links
 ::  Similar in PUBMED
 ::  Search Pubmed for
 ::  Search in Google Scholar for
 ::  Article in PDF (216 KB)
 ::  Citation Manager
 ::  Access Statistics
 ::  Reader Comments
 ::  Email Alert *
 ::  Add to My List *
* Registration required (free) 

  IN THIS Article
 ::  References

 Article Access Statistics
    Viewed276    
    Printed7    
    Emailed0    
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal


 


 
  Table of Contents     
EDITORIAL COMMENTARY
Year : 2017  |  Volume : 63  |  Issue : 4  |  Page : 210-212

Topical therapy of psoriasis: Where do we stand?


Department of Dermatology and STD, JIPMER, Puducherry, India

Date of Web Publication11-Oct-2017

Correspondence Address:
D M Thappa
Department of Dermatology and STD, JIPMER, Puducherry
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jpgm.JPGM_155_17

Rights and Permissions




How to cite this article:
Thappa D M, Malathi M. Topical therapy of psoriasis: Where do we stand?. J Postgrad Med 2017;63:210-2

How to cite this URL:
Thappa D M, Malathi M. Topical therapy of psoriasis: Where do we stand?. J Postgrad Med [serial online] 2017 [cited 2017 Oct 22];63:210-2. Available from: http://www.jpgmonline.com/text.asp?2017/63/4/210/216436




Psoriasis, an immune-mediated inflammatory disorder with genetic and environmental influences, is a common, chronic, disfiguring, inflammatory, and proliferative condition of the skin, characterized by well-defined erythematous, scaly indurated plaques predominantly affecting the scalp, and extensor surfaces.[1] Despite psoriasis being a benign and noncontagious condition, it significantly affects the quality of life of patients owing to the cosmetically disfiguring nature of the lesions. Based on the extent of involvement and affection of quality of life, the treatment of psoriasis is individualized with either topical therapy for mild-to-moderate cases and phototherapy or systemic therapy for moderate-to-severe cases.

The majority of patients with psoriasis have limited disease, which can be managed with topical therapies alone. Thus, topical therapy plays a very important role in the therapeutic armamentarium of psoriasis, and it is not only limited as monotherapy in the treatment of mild and localized lesions but also has an adjuvant role in the treatment of lesions in specific locations and for residual lesions during or after treatment with phototherapy or systemic therapy including biologics. This strategy of combining topical therapy with systemic and phototherapy results in additional and immediate symptom relief, reduction in the dose of systemic medications, and better psychological comfort to patients.[2],[3],[4],[5],[6]

The various topical therapeutic agents used in psoriasis include emollients, keratolytic agents such as salicylic acid, coal tar, dithranol, corticosteroids, Vitamin D analogs, retinoids, and immunomodulators such as tacrolimus and pimecrolimus.[1],[2],[3],[4],[5],[6] Recommendations based on evidence-based data suggest class I corticosteroids, Vitamin D analogs, tazarotene, and combinations of either corticosteroids and Vitamin D analog or corticosteroids and tazarotene as class A rank drugs (evidence based on large, prospective, double-blind studies and consistent and good-quality patient-oriented evidence) that are statistically superior to other topical therapies.[2],[5] Other agents that have been tried in topical therapy of psoriasis include 5-fluorouracil, ascomycin derivative, methotrexate, and leukotriene inhibitors.[7]

Despite their proven efficacy and safety in psoriasis, there is a continued need for more effective and better tolerated agents with different mechanisms of action for the treatment of recalcitrant lesions and for improved patient adherence. These newer developments include newer combinations, better formulations, newer investigational agents, or a comeback of older traditional therapies.

The need for newer and better formulations to improve topical drug-delivery systems cannot be understated owing to the unique nature of drug delivery across the skin which affects the pharmacokinetics of the drug. This is of special relevance in psoriasis, wherein the heterogeneity of the skin lesions with both thickened and markedly thinned epidermis can increase the variability in drug permeation and systemic absorption, thereby posing challenges in formulation development. Reduced drug concentration can also occur due to presystemic metabolism of the drug in the skin. High variability in in vitro and in vivo skin permeability also adds to the obstacle in formulation development. Hence, failure to choose the optimal topical formulation appropriate for the morphology and site might contribute to poor treatment outcomes. Thus, newer topical formulations should have improved drug-delivery mechanisms with appropriate cosmetic elegance which can be used on many areas of the body including hair-bearing sites to ensure therapeutic efficacy and improved adherence.[8] Liposomes, microemulsions, solid lipid nanoparticles, nanostructured lipid carriers, and micelles may have the potential to encapsulate antipsoriatic drugs for topical application. In addition, techniques such as iontophoresis, electroporation, and lasers can be used to enhance penetration of the stratum corneum.[9]

The investigational topical agents for psoriasis target the small molecules that modulate proinflammatory cytokines and selectively inhibit signaling pathways which include inhibitors of phosphodiesterase 4, integrin, Janus kinase (JAK) 1/JAK2 (ruxolitinib, tofacitinib), and tyrosine kinase.[2],[10] AN2728, a boron-based phosphodiesterase 4 inhibitor with anti-inflammatory property, has been administered topically in phase 2 studies to patients with psoriasis.[11] JAK inhibitors, being small molecules, can easily penetrate the epidermal barrier and hence are used in topical formulations. Tofacitinib, a pan-JAK inhibitor with predominant anti-JAK3 effect, and ruxolitinib, a JAK1/2 inhibitor, have shown promising results in the topical treatment of mild-to-moderate psoriasis.[12] CT327, a tyrosine-kinase A inhibitor in a topical formulation, has been reported to be safe and well tolerated, causing a significant reduction in pruritus.[10] Methotrexate, the dihydrofolate reductase, has been developed as a nanogel composed of methotrexate-loaded nanostructured lipid carrier for topical application and has been reported as a promising alternative to the existing methotrexate formulation in treating psoriasis.[13]

The traditional therapy with immunomodulatory property which is being currently investigated in the topical therapy of psoriasis is Saint John's wort (SJW) (Hypericum perforatum). It is a traditional herbal medicine which has been used topically as oils or tinctures for the treatment of minor wounds and burns, sunburns, abrasions, bruises, contusions, ulcers, and myalgia and orally for the treatment of depression with pharmacologic research supporting its use in these indications.[14] Owing to the antioxidant, anti-inflammatory, anticancer, antimicrobial, and photosensitizing properties as well as the effect on keratinocyte proliferation and differentiation, SJW has been investigated in the treatment of dermatological disorders such as atopic dermatitis, psoriasis, herpes infections, and nonmelanoma skin cancer.[14] These properties are attributed to the active constituents of SJW, namely, the naphthodianthrone derivative hypericin and the phloroglucin derivative hyperforin.[15] The effect of SJW in psoriasis is due to the hyperforin derivative which displays anti-inflammatory activity on T-cells and stimulation of keratinocyte differentiation. These effects of hyperforin are mediated by the effects on cell signaling or production of cytokines, rather than merely toxic effects especially by regulation of CD8-mediated cytotoxicity and inhibition of tumor necrosis factor (TNFα)-induced apoptosis. Moreover, owing to the photosensitizing property of hypericin, SJW can be considered as a viable investigational agent for photodynamic therapy in psoriasis.[16] SJW was reported to be effective in reducing psoriasis area severity index scores in mild plaque-type psoriasis when compared to placebo in a case series. However, large, well-conducted trials are required to provide conclusive evidence.[16]

Taking cue of these facts, Mansouri et al.[17] have formulated an ointment with added extract of H. perforatum in vaseline, propylene glycol, and avicel for the treatment of mild-to-moderate psoriasis. They have conducted a double-blind placebo controlled study to investigate the effects of topical H. perforatum on TNF levels in psoriatic lesions for possible identification of the mechanism by which Hypericum reduces inflammation and modulates the disease in patients with plaque-type psoriasis. They have observed that H. perforatum in the ointment decreases the TNFα levels in psoriatic lesions, thereby proving that the beneficial effect of SJW in psoriasis is probably directly or indirectly associated with its effects on lowering cytokines including TNFα.[17] Although the study design selected was appropriate, the study was not sufficiently powered due to the small sample size. The results obtained from their study need to be validated with a larger sample size. If the efficacy of this topical agent is proven in future studies, it can be included in the armamentarium of topical agents used for the management of mild-to-moderate plaque type of psoriasis.

To conclude, topical therapeutic agents in psoriasis have come a long way from traditional therapies to newer investigational therapies owing to advances in the understanding of the pathogenesis of psoriasis. In addition, significant efforts have been made to improve the efficacy, tolerability, and patient adherence by implementing better drug combinations and formulations. Despite all the developments, symptom reduction, cosmetic clearing of the skin, and better quality of life still remain a challenge for dermatologists warranting continuous research for identifying newer treatments.



 
 :: References Top

1.
Burden AD, Kirby B. Psoriasis and related disorders. In: Griffiths CE, Barker J, Bleiker T, Chalmers R, Creamer D, editors. Rook's Textbook of Dermatology. 9th ed. Oxford: Wiley Blackwell; 2016. p. 35.1-35.46.  Back to cited text no. 1
    
2.
Stein Gold LF. Topical therapies for psoriasis: Improving management strategies and patient adherence. Semin Cutan Med Surg 2016;35:S36-44.  Back to cited text no. 2
    
3.
Puig L, Carrascosa JM, Belinchón I, Fernández-Redondo V, Carretero G, Ruiz-Carrascosa JC, et al. Adherence and patient satisfaction with topical treatment in psoriasis, and the use, and organoleptic properties of such treatments: A Delphi study with an expert panel and members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr 2013;104:488-96.  Back to cited text no. 3
    
4.
Feldman SR, Horn EJ, Balkrishnan R, Basra MK, Finlay AY, McCoy D, et al. Psoriasis: Improving adherence to topical therapy. J Am Acad Dermatol 2008;59:1009-16.  Back to cited text no. 4
    
5.
Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009;60:643-59.  Back to cited text no. 5
    
6.
Lebwohl M, Ting PT, Koo JY. Psoriasis treatment: Traditional therapy. Ann Rheum Dis 2005;64 Suppl 2:ii83-6.  Back to cited text no. 6
    
7.
Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001;45:487-98.  Back to cited text no. 7
    
8.
Mitra A, Atillasoy E. Topical therapies for psoriasis. In: Soung J, editor. Psoriasis, Croatia/Shangai: InTech; 2012. Available from: http://www.intechopen.com/books/psoriasis/topical-therapies-for-psoriasis. [Last accessed on 2017 Jun 30].  Back to cited text no. 8
    
9.
Su YH, Fang JY. Drug delivery and formulations for the topical treatment of psoriasis. Expert Opin Drug Deliv 2008;5:235-49.  Back to cited text no. 9
    
10.
Torres T, Filipe P. Small molecules in the treatment of psoriasis. Drug Dev Res 2015;76:215-27.  Back to cited text no. 10
    
11.
Nazarian R, Weinberg JM. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs 2009;10:1236-42.  Back to cited text no. 11
    
12.
Alves de Medeiros AK, Speeckaert R, Desmet E, Van Gele M, De Schepper S, Lambert J, et al. JAK3 as an emerging target for topical treatment of inflammatory skin diseases. PLoS One 2016;11:e0164080.  Back to cited text no. 12
    
13.
Avasatthi V, Pawar H, Dora CP, Bansod P, Gill MS, Suresh S, et al. A novel nanogel formulation of methotrexate for topical treatment of psoriasis: Optimization, in vitro and in vivo evaluation. Pharm Dev Technol 2016;21:554-62.  Back to cited text no. 13
    
14.
Wölfle U, Seelinger G, Schempp CM. Topical application of st. john's wort (Hypericum perforatum). Planta Med 2014;80:109-20.  Back to cited text no. 14
    
15.
Schempp CM, Winghofer B, Lüdtke R, Simon-Haarhaus B, Schöpf E, Simon JC, et al. Topical application of St. John's wort (Hypericum perforatum L.) and of its metabolite hyperforin inhibits the allostimulatory capacity of epidermal cells. Br J Dermatol 2000;142:979-84.  Back to cited text no. 15
    
16.
Najafizadeh P, Hashemian F, Mansouri P, Farshi S, Surmaghi MS, Chalangari R, et al. The evaluation of the clinical effect of topical St. Johns wort (Hypericum perforatum L.) in plaque type psoriasis vulgaris: A pilot study. Australas J Dermatol 2012;53:131-5.  Back to cited text no. 16
    
17.
Mansouri P, Mirafzal S, Najafizadeh P, Safaei-Naraghi Z, Salehi-Surmaghi MH, Hashemian F. The impact of topical Saint John's wort (Hypericum perforatum) treatment on tissue tumor necrosis factor-alpha levels in plaque-type psoriasis: A pilot study. J Postgrad Med 2017;63:215-20.  Back to cited text no. 17
[PUBMED]  [Full text]  




 

Top
Print this article  Email this article
 
Online since 12th February '04
2004 - Journal of Postgraduate Medicine
Official Publication of the Staff Society of the Seth GS Medical College and KEM Hospital, Mumbai, India
Published by Wolters Kluwer - Medknow